; and (B) an assessment of the resilience and capacity of the current supply chain and industrial base to support national defense if no pharmaceutical products purchased for beneficiaries of health care from the Department of Defense or any associated program are made in part or in whole in China, including with respect to— (i) the manufacturing capacity of the United States; (ii) gaps in domestic manufacturing capabilities, including non-existent, extinct, threatened, and single-point-of-failure capabilities; and (iii) supply chains with single points of failure and limited resiliency. (2) Required recommendations The assessment under paragraph (1)(B) shall include recommendations— (A) to address critical bottlenecks in the supply of pharmaceutical products in the United States